undamentalytics Newsletter

Baker Julian: insider trades

Director, 10% owner, Other at 8 companies we cover. 12 open-market purchases and 6 sales not made under a pre-set plan, reported from August 11, 2010 to September 30, 2026.

Would copying Baker Julian’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 11 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on December 2, 2011 into $32,386 by November 2, 2026, +8.2% a year. The copy held shares only 41% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $36,212, +9.0% a year (the S&P 500 held throughout made $78,673, +14.9% a year). Beta against the index was 0.66. Twelve months after each report, the average purchase was +14.5% against the S&P 500 (median +14.9%), and 64% beat it. Measured from the trade date, the insider’s own timing, the average was +17.7%. After their sales, the shares moved −6.3% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$25.0k$50.0k$75.0k 20112013201520172019202120232025 $78.7k$36.2k$32.4k
Copying Baker JulianS&P 500, same days investedS&P 500, held throughout $10,000 copying Baker Julian’s open-market purchases from December 2, 2011, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+8.2%
S&P 500, same days invested
+9.0% (held throughout +14.9%)
Time in shares
41%
Sharpe ratio (S&P 500)
0.36 (0.82)
Biggest drop (S&P 500)
−71% (−34%)
Market sensitivity (beta)
0.66
Purchases copied
12

Trade by trade

Baker Julian: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 11 +13.5% +10.4% 73% 6 1.12 0.31 No reliable evidence
Purchases, 6 months after the report 11 +17.8% +14.9% 73% 6 1.80 0.13 No reliable evidence
Purchases, 12 months after the report 11 +14.5% +14.9% 64% 6 1.40 0.22 No reliable evidence
Purchases, 12 months after the trade 11 +17.7% +21.4% 73% 6 1.75 0.14 No reliable evidence
Sales, 3 months after the report 4 −2.3% +7.4% 25% 2 — — Not enough years
Sales, 12 months after the report 3 −6.3% −4.7% 100% 1 — — Not enough years
Sales, 12 months after the trade 3 −9.4% −8.1% 100% 1 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Incyte INCY —43August 11, 2010February 14, 2022
Kodiak Sciences Inc. KOD —30February 26, 2020September 30, 2026
Biocryst Pharmaceuticals Inc BCRX —11January 29, 2016August 16, 2016
Madrigal Pharmaceuticals, Inc. MDGL —20November 15, 2023November 21, 2023
Acadia Pharmaceuticals Inc ACAD —10January 8, 2016January 8, 2016
Neurogene Inc. NGNE —10December 23, 2020December 23, 2020
Kala BIO, Inc. KALA —01October 2, 2025October 2, 2025
Celcuity Inc. CELC —01July 16, 2026July 16, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
September 30, 2026September 28, 2026 KOD Purchase $34,962,746 not yetnot yetnot yet
July 16, 2026July 14, 2026 CELC Sale $317,750,000 −35.9%not yetnot yet
October 2, 2025September 30, 2025 KALA Sale $1,055,659 not yetnot yetnot yet
November 21, 2023November 21, 2023 MDGL Purchase $12,128,192 +10.4%+49.8%+42.0%
November 15, 2023November 14, 2023 MDGL Purchase $7,809,469 +25.4%+47.5%+59.4%
February 14, 2022February 10, 2022 INCY Purchase $106,952,146 +20.1%+22.9%+26.3%
December 23, 2020July 7, 2020 NGNE Purchase $6,466,000 −26.7%−93.6%−78.1%
September 8, 2020September 3, 2020 KOD Purchase $15,319,093 +143.8%+54.8%+60.4%
February 26, 2020February 24, 2020 KOD Purchase $21,829,862 +6.5%+93.8%+84.3%
August 16, 2016August 12, 2016 BCRX Sale $20,250,647 not yetnot yetnot yet
January 29, 2016January 27, 2016 BCRX Purchase $614,148 −58.2%−28.7%−32.4%
January 8, 2016January 7, 2016 ACAD Purchase $74,999,974 +11.2%−4.3%−6.0%
January 17, 2012January 12, 2012 INCY Purchase $239,435 −5.0%−6.8%+2.9%
December 7, 2011December 5, 2011 INCY Purchase $572,197 +11.9%+14.9%+13.9%
December 1, 2011November 29, 2011 INCY Purchase $668,797 +9.0%+9.6%+21.5%
September 23, 2010September 21, 2010 INCY Sale $321,631 +2.6%−9.4%−11.9%
August 11, 2010August 9, 2010 INCY Sale $5,652,534 +12.1%−4.7%−8.1%
August 11, 2010August 9, 2010 INCY Sale $120,218 +12.1%−4.7%−8.1%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Baker Julian traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.